Literature DB >> 20461149

Ocular manifestations of branchio-oculo-facial syndrome: report of a novel mutation and review of the literature.

M S Al-Dosari1, M Almazyad, L Al-Ebdi, J Y Mohamed, Saad Al-Dahmash, Hassan Al-Dhibi, Eman Al-Kahtani, Shahira Al-Turkmani, Hisham Alkuraya, B D Hall, F S Alkuraya.   

Abstract

PURPOSE: To report unusual ocular manifestations of branchio-oculo-facial syndrome (BOFS) caused by a novel mutation in activating enhancer binding protein 2 alpha (TFAP2A).
METHODS: Full ophthalmological evaluation and direct sequencing of TFAP2A.
RESULTS: A 10-year-old girl with unusual ocular manifestations of BOFS such as elliptical shaped microcornea and a novel de novo TFAP2A mutation was identified.
CONCLUSIONS: This report expands the ocular phenotypic spectrum of BOFS and adds to the small number of reported TFAP2A mutations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20461149      PMCID: PMC2866573     

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  26 in total

1.  Another case of preaxial polydactyly and white forelock in branchio-oculo-facial syndrome.

Authors:  J McGaughran
Journal:  Clin Dysmorphol       Date:  2001-01       Impact factor: 0.816

2.  AP-2alpha transcription factor is required for early morphogenesis of the lens vesicle.

Authors:  J A West-Mays; J Zhang; T Nottoli; S Hagopian-Donaldson; D Libby; K J Strissel; T Williams
Journal:  Dev Biol       Date:  1999-02-01       Impact factor: 3.582

Review 3.  New autosomal dominant branchio-oculo-facial syndrome.

Authors:  A Fujimoto; M Lipson; R V Lacro; N W Shinno; W D Boelter; K L Jones; M G Wilson
Journal:  Am J Med Genet       Date:  1987-08

4.  Exclusion of the branchio-oto-renal syndrome locus (EYA1) from patients with branchio-oculo-facial syndrome.

Authors:  A E Lin; E V Semina; S Daack-Hirsch; E R Roeder; C J Curry; K Rosenbaum; D D Weaver; J C Murray
Journal:  Am J Med Genet       Date:  2000-04-24

5.  Ocular anomalies in the branchio-oculo-facial syndrome.

Authors:  C S Su; S B O'Hagen; T J Sullivan
Journal:  Aust N Z J Ophthalmol       Date:  1998-02

6.  Branchio-oculo-facial syndrome associated with a white forelock.

Authors:  A Mégarbané; N Hawat; P Chedid; J Bleik; A L Délézoïde
Journal:  Clin Dysmorphol       Date:  1998-07       Impact factor: 0.816

7.  An ENU-induced mutation in AP-2alpha leads to middle ear and ocular defects in Doarad mice.

Authors:  Nadav Ahituv; Alexandra Erven; Helmut Fuchs; Keren Guy; Ruth Ashery-Padan; Trevor Williams; Martin Hrabe de Angelis; Karen B Avraham; Karen P Steel
Journal:  Mamm Genome       Date:  2004-06       Impact factor: 2.957

8.  Treatment of otorhinolaryngological manifestations of three rare genetic syndromes: Branchio-Oculo-Facial (BOF), Ectrodactyly Ectodermal dysplasia Clefting (EEC) and focal dermal hypoplasia (Goltz syndrome).

Authors:  Henryk Skarzynski; Robert Podskarbi-Fayette
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2008-11-13       Impact factor: 1.675

9.  Branchio-oculo-facial syndrome with cleft lip and bilateral dermal thymus.

Authors:  S Bennaceur; T Buisson; C Bertolus; G Couly
Journal:  Cleft Palate Craniofac J       Date:  1998-09

Review 10.  Further delineation of the branchio-oculo-facial syndrome.

Authors:  A E Lin; R J Gorlin; I W Lurie; H G Brunner; I van der Burgt; I V Naumchik; N V Rumyantseva; S Stengel-Rutkowski; K Rosenbaum; P Meinecke
Journal:  Am J Med Genet       Date:  1995-03-13
View more
  2 in total

1.  Implication of the miR-184 and miR-204 competitive RNA network in control of mouse secondary cataract.

Authors:  Andrea Hoffmann; Yusen Huang; Rinako Suetsugu-Maki; Carol S Ringelberg; Craig R Tomlinson; Katia Del Rio-Tsonis; Panagiotis A Tsonis
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

2.  Analysis of TFAP2A mutations in Branchio-Oculo-Facial Syndrome indicates functional complexity within the AP-2α DNA-binding domain.

Authors:  Hong Li; Ryan Sheridan; Trevor Williams
Journal:  Hum Mol Genet       Date:  2013-04-10       Impact factor: 6.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.